A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

229

Enrollment

INDUSTRY

Sponsor class

Conditions

Coeliac Disease
Celiac Disease

Interventions

DRUG: Amlitelimab
DRUG: Placebo
DIETARY_SUPPLEMENT: SIGE
DIETARY_SUPPLEMENT: Gluten-free product (GFP)

Sponsor

Sanofi